Related Experiment Videos
Trichothecene analogues. 1. 1,5-Dioxaspiro(2.5)octanes
Journal of Medicinal Chemistry
|December 1, 1976
Summary
Seven novel spirooctane compounds were synthesized and tested for anticancer activity. While showing moderate efficacy against certain tumors, they lacked the toxicity of related compounds.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Organic Synthesis
Background:
- The "epoxypyran" structure is a key feature of trichothecene sesquiterpenes, known for their tumor-inhibiting properties.
- Understanding the structure-activity relationship of these compounds is crucial for developing new anticancer agents.
Purpose of the Study:
- To synthesize and evaluate the anticancer potential of seven 1,5-dioxaspiro[2.5]octanes.
- To compare the activity and toxicity of these novel compounds against established antitumor agents.
Main Methods:
- Synthesis of seven 1,5-dioxaspiro[2.5]octane derivatives.
- Anticancer screening using the mouse P388 lymphocytic leukemia and Ehrlich ascites tumor models.
- Assessment of skin irritation in rabbits as a measure of toxicity.
Main Results:
- Three synthesized spirooctanes exhibited marginal to moderate activity (74.1-86.3% inhibition) in the Ehrlich ascites screen and low activity (T/C = 126-131) in the P388 screen.
- A carbocyclic analogue, 1-oxaspiro[2.5]octane (9), showed moderate activity in both screens (78.8% inhibition, T/C = 140).
- Compound 9 was significantly less potent than T-2 toxin in the Ehrlich ascites screen and demonstrated a favorable safety profile, with no skin irritation at 10-mg doses, unlike T-2 toxin.
Conclusions:
- The tested 1,5-dioxaspiro[2.5]octanes possess anticancer activity, though generally less potent than T-2 toxin.
- The carbocyclic analogue (9) presents a promising profile with moderate efficacy and reduced toxicity, warranting further investigation.
- These findings contribute to understanding the role of the epoxypyran moiety in antitumor activity and suggest potential for developing safer chemotherapeutic agents.